Tacrolimus and pimecrolimus for atopic eczema

Clarification of guidance on the use of tacrolimus and pimecrolimus for atopic eczema 

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: review decision - July 2015 information

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: appendix A - static list review decision - July 2015

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: appendix A - static list review decision - July 2015 (PDF 174 KB)

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report 

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report (PDF 1.64 MB)

Review proposal information

Review decision- December 2007 information

Review proposal for TA82: provisional consultees and commentators

Review proposal for TA82: provisional consultees and commentators (PDF 58 KB)

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: comments table

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: comments table (PDF 40 KB)

Review proposal - April 2009 information

Comments table - April 2009

Comments table - April 2009 (PDF 45 KB)

Review decision - June 2009 information

Final Appraisal Determination: Tacrolimus and pimecrolimus for atopic eczema information

Final Appraisal Determination

Final Appraisal Determination (PDF 174 KB)

Additional analysis on the assessment report - prepared by PenTAG

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report 

Protocol for the appraisal of pimecrolimus and tacrolimus for atopic eczema

2003/009 NICE asked to develop guidance on treating eczema, support programmes for parents dealing with conduct disorder in children, use of statins for heart disease, and when hysterectomy is appropriate information